var data={"title":"Fluorometholone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluorometholone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6214?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluorometholone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluorometholone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=fluorometholone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluorometholone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172523\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Flarex;</li>\n      <li>FML;</li>\n      <li>FML Forte;</li>\n      <li>FML Liquifilm</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172524\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Flarex;</li>\n      <li>FML;</li>\n      <li>FML Forte;</li>\n      <li>PMS-Fluorometholone;</li>\n      <li>Sandoz-Fluorometholone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172559\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Ophthalmic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172525\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Ocular inflammation:</b> Ophthalmic:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ointment: Apply small amount (~<sup>1</sup>/<sub>2</sub> inch ribbon) to conjunctival sac 1 to 3 times daily; may increase application to every 4 hours during the initial 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.1%: Instill 1 to 2 drops into conjunctival sac 2 to 4 times daily; may instill 2 drops every 2 hours or 1 drop every 4 hours during initial 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.25%: Instill 1 drop into conjunctival sac 2 to 4 times daily; may instill 1 drop every 4 hours during initial 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Re-evaluate therapy if improvement is not seen within 2 to 14 days (product specific); use care not to discontinue prematurely; in chronic conditions, gradually decrease dosing frequency prior to discontinuing treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172542\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=fluorometholone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluorometholone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Ocular inflammation:</b> Children &ge;2 years and Adolescents: Ophthalmic: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172526\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15896228\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15896229\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172511\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, Ophthalmic, as base: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FML: 0.1% (3.5 g) [contains phenylmercuric acetate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Ophthalmic, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flarex: 0.1% (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Ophthalmic, as base: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FML Forte: 0.25% (5 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FML Liquifilm: 0.1% (5 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (5 mL, 10 mL, 15 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172496\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4844876\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Ophthalmic: For topical ophthalmic use only; to avoid contamination, do not touch dropper or tube tip to eyelids or other surfaces. Remove contacts prior to administration and wait 15 minutes before reinserting. Shake suspension well before using.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172512\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Ocular inflammation:</b> Treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3197884\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flarex [US, Canada, and multiple international markets] may be confused with Fluarix brand name for influenza virus vaccine (inactivated) [US and multiple international markets] and Fluorex brand name for fluoride [France]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172503\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hypercorticoidism (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Dysgeusia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Bacterial eye infection (secondary), blurred vision, burning sensation of eyes, cataract, decreased visual acuity, erythema of eyelid, eye discharge, eye irritation, eyelid edema, eye pain, eye pruritus, foreign body sensation of eye, fungal eye infection (secondary), glaucoma, increased intraocular pressure, increased lacrimation, optic nerve damage, stinging of eyes, swelling of eye, viral eye infection (secondary), visual field defect, wound healing impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172515\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to fluorometholone, other corticosteroids, or any component of the formulation; viral diseases of the cornea and conjunctiva (including epithelial herpes simplex keratitis, vaccinia, and varicella); mycobacterial or fungal infections of the eye; acute purulent untreated eye infections which may be masked/enhanced by a steroid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172500\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. Use following cataract surgery may delay healing or increase the incidence of bleb formation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Corneal thinning: Various ophthalmic disorders, as well as prolonged use of corticosteroids, may result in corneal and scleral thinning. Continued use in a patient with thinning may result in perforation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Prolonged use of corticosteroids may result in elevated intraocular pressure (IOP) and/or glaucoma; damage to the optic nerve; and defects in visual acuity and fields of vision. Use with caution in patients with glaucoma; monitor IOP in any patient receiving treatment for &ge;10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection (including fungal infections). Acute purulent ocular infections may be masked or exacerbated with use. Fungal infection should be suspected in any patient with persistent corneal ulceration who has received corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Disease-related concerns:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Herpes simplex: Use caution in patients with history of herpes simplex; frequent slit lamp microscopy is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: Some products contain benzalkonium chloride which may be adsorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Patients should be re-evaluated if symptoms fail to improve after 2 to 14 days (product specific). Initial prescription and renewal of medication &gt;20 mL (suspension) or &gt;8 g (ointment) should be made by health care provider only after examination with the aid of magnification such as slit lamp biomicroscopy or fluorescein staining (if appropriate).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: In chronic conditions, withdraw therapy with gradual tapering of dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299353\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172505\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8463&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172507\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172517\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies following use of ophthalmic fluorometholone. The extent of systemic absorption following topical application of the ophthalmic drops is not known. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus (Samples 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14877584\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Systemic corticosteroids are excreted in human milk. The extent of systemic absorption following topical application of the ophthalmic drops is not known. The manufacturer recommends that caution be exercised when administering fluorometholone to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172509\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Intraocular pressure when used for &ge;10 days; signs or symptoms of infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172499\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Corticosteroids inhibit the inflammatory response including edema, capillary dilation, leukocyte migration, and scar formation. Fluorometholone penetrates cells readily to induce the production of lipocortins. These proteins modulate the activity of prostaglandins and leukotrienes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172514\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Absorption: Primarily into aqueous humor (Hui 1986)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172516\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (FML Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (3.5 g): $174.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Flarex Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (5 mL): $84.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Fluorometholone Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (5 mL): $85.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (FML Forte Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (5 mL): $174.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (FML Liquifilm Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (5 mL): $174.74</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172518\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aflarex (CL, CO, PE, VE);</li>\n      <li>Afm (BD);</li>\n      <li>Efflumidex (BG, CZ, DE, HR, HU);</li>\n      <li>F.M.L. (UY);</li>\n      <li>Flarex (AE, AR, AT, AU, BF, BG, BH, BJ, CI, CN, CY, CZ, EG, ET, GH, GM, GN, HK, HN, IL, IQ, IR, IT, JO, KE, KR, KW, LB, LK, LR, LT, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, OM, PH, PL, PY, QA, RU, SA, SC, SD, SL, SN, SY, TH, TN, TW, TZ, UG, VN, YE, ZM, ZW);</li>\n      <li>Florate (BR);</li>\n      <li>Florom (PK);</li>\n      <li>Flosef (IN);</li>\n      <li>Flu Oph (TH);</li>\n      <li>Flu-Base (JP);</li>\n      <li>Fluaton (IT);</li>\n      <li>Flucon (AU, BE, CH, CZ, FR, GR, HK, HU, LU, NZ, PT, TH, TR, TW);</li>\n      <li>Fluforte (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Flulon (PH);</li>\n      <li>Flumelon (KR);</li>\n      <li>Flumetholon (HK, JP, KR, TW);</li>\n      <li>Flumetholone (KR);</li>\n      <li>Flumetol (QA, RO);</li>\n      <li>Flumetol NF Ofteno (MX);</li>\n      <li>Flumex (BR, CO, EC);</li>\n      <li>Fluoftal (CO);</li>\n      <li>Fluoropos (KR);</li>\n      <li>Flurolon (DK);</li>\n      <li>Flurom (BD);</li>\n      <li>FML (AE, AR, BB, BE, BH, CN, CY, EG, ES, GB, GR, HK, IE, IL, IQ, IR, JO, KW, LB, LK, LY, MY, OM, PE, PH, QA, SA, SG, SY, TH, TW, VN, YE, ZA, ZW);</li>\n      <li>FML Damla (TR);</li>\n      <li>FML Liquifilm (AU, CH, FI, LU, NL, NZ);</li>\n      <li>Fuluson (KR);</li>\n      <li>Fumelon (KR);</li>\n      <li>Inomet (BD);</li>\n      <li>Isopto Flucon (ES);</li>\n      <li>Medoflucon (SK);</li>\n      <li>Ocuflam (ID);</li>\n      <li>Ocumetholone (KR, PH);</li>\n      <li>Okilon (JP);</li>\n      <li>Optiflur (LK);</li>\n      <li>Optilone (AE, BH, QA, SA);</li>\n      <li>Rubalon (BD);</li>\n      <li>Ursnon (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Flarex (fluorometholone acetate) [prescribing information]. Fort Worth, TX: Alcon Laboratories Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flarex (fluorometholone acetate) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FML (fluorometholone) [product monograph]. Markham, Ontario, Canada; Allergan Inc; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FML Forte (fluorometholone) [product monograph]. Markham, Ontario, Canada; Allergan Inc; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hui HW, Robinson JR. Effect of particle dissolution rate on ocular drug bioavailability. <i>J Pharm Sci</i>. 1986;75(3):280-287.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorometholone-drug-information/abstract-text/3701612/pubmed\" target=\"_blank\" id=\"3701612\">3701612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorometholone-drug-information/abstract-text/2903673/pubmed\" target=\"_blank\" id=\"2903673\">2903673</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8463 Version 138.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F172523\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F172524\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F172559\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F172525\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F172542\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F172526\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15896228\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15896229\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F172511\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F172496\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F4844876\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F172512\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3197884\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F172503\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F172515\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F172500\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299353\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F172505\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F172507\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F172517\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14877584\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F172509\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F172499\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F172514\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F172516\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F172518\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8463|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluorometholone-patient-drug-information\" class=\"drug drug_patient\">Fluorometholone: Patient drug information</a></li><li><a href=\"topic.htm?path=fluorometholone-pediatric-drug-information\" class=\"drug drug_pediatric\">Fluorometholone: Pediatric drug information</a></li></ul></div></div>","javascript":null}